|
ASN; PRIMO study shows no benefits of paricalcitol on LVH in patients. |
 |
|
MedPage: As expected, paricalcitol did reduce intact parathyroid hormone levels throughout the study, showing that the patients were compliant with treatment. That did not, however, translate into a reduction in cardiac hypertrophy, which was the primary outcome. The size of the left ventricle -- indexed to height -- went down slightly in the placebo group and remained the same in the paricalcitol group, although the difference between the groups was not statistically significant (P=0.061)
|